

SOMETHING BETTER THAN HOPE

Amendments to DISC2 and CLIN2 Concept Proposals

Gil Sambrano

Vice President
Portfolio Development and Review

July 22, 2020

CIRM
CALIFORNIA / STEM CELL AGENCY

Background

- At the June 26, 2020 meeting of the Governing Board, the Board approved a budget allocation of \$2M for a launching of the DISC2 funding opportunity and the allocation of all remaining and future unallocated research funds to the CLIN2 funding opportunity
- CIRM is proposing changes to the DISC2 and CLIN2 concepts to effectively implement these programs within CIRM's operational timeline and allocated budget

Proposed Changes to DISC2 Program

Discovery awards to identify a candidate therapeutic, medical device, diagnostic, or tool

- Award limit of \$250,000
- Maximum award duration of 12 months
- Reduce the PI percent effort requirement to 10%
- Initiate projects within 30 days of approval
- Requirement to provide a statement describing how the study plan and design has considered the influence of race, ethnicity, sex and gender diversity

Proposed Changes to CLIN2 Program*

Awards to support a clinical trial

- Adjust award limit to 75% of previous caps
- Adjust the award duration to not exceed 3 years with award completion no later than (November 2023)
- Initiate projects within 30 days of approval
- Requirement to provide a written plan in the application for outreach and study participation by underserved and disproportionately affected populations

*Proposed changes do not apply to sickle cell disease projects under the CIRM/NHLBI Cure Sickle Cell Disease Joint Initiative

Requested Action

CIRM requests the Board approve the proposed amendments to the DISC and CLIN concept plans.